Loading...

Deltex Medical Group

DB:DX9
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DX9
DB
£4M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Deltex Medical Group plc manufactures and sells oesophageal doppler monitoring (ODM) systems in the United Kingdom, the United States, Spain, Canada, and internationally. The last earnings update was 111 days ago. More info.


Add to Portfolio Compare Print
DX9 Share Price and Events
7 Day Returns
0%
DB:DX9
-1.8%
DE Medical Equipment
1.2%
DE Market
1 Year Returns
250%
DB:DX9
14.7%
DE Medical Equipment
-19.1%
DE Market
DX9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Deltex Medical Group (DX9) 0% 0% 16.7% 250% -86.3% -95.2%
DE Medical Equipment -1.8% -7.2% 1.9% 14.7% 70% 142%
DE Market 1.2% -0.7% -4.6% -19.1% 7.1% 0.3%
1 Year Return vs Industry and Market
  • DX9 outperformed the Medical Equipment industry which returned 14.7% over the past year.
  • DX9 outperformed the Market in Germany which returned -19.1% over the past year.
Price Volatility
DX9
Industry
5yr Volatility vs Market

DX9 Value

 Is Deltex Medical Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Deltex Medical Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Deltex Medical Group.

DB:DX9 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:DX9
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.43
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.431 (1 + (1- 19%) (42.17%))
0.578
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (0.8 * 9.46%)
8.11%

Discounted Cash Flow Calculation for DB:DX9 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Deltex Medical Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:DX9 DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (GBP, Millions) 0.25 0.24 0.23 0.22 0.21
Source Analyst x1 Est @ -3.77% Est @ -3.77% Est @ -3.77% Est @ -3.77%
Present Value
Discounted (@ 8.11%)
0.23 0.21 0.18 0.16 0.15
Present value of next 5 years cash flows £0.93
DB:DX9 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= £0.21 × (1 + 0.54%) ÷ (8.11% – 0.54%)
£2.85
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= £2.85 ÷ (1 + 8.11%)5
£1.93
DB:DX9 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= £0.93 + £1.93
£2.86
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £2.86 / 492.66
£0
DB:DX9 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:DX9 represents 0.73684x of AIM:DEMG
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.73684x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (GBP) x Listing Adjustment Factor
= £ 0.01 x 0.73684
€0.00
Value per share (EUR) From above. €0.00
Current discount Discount to share price of €0.01
= -1 x (€0.01 - €0.00) / €0.00
-63.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Deltex Medical Group is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Deltex Medical Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Deltex Medical Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:DX9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in GBP £-0.01
AIM:DEMG Share Price ** AIM (2018-10-16) in GBP £0.01
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 27.75x
Germany Market PE Ratio Median Figure of 417 Publicly-Listed Companies 17.08x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Deltex Medical Group.

DB:DX9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:DEMG Share Price ÷ EPS (both in GBP)

= 0.01 ÷ -0.01

-1.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Deltex Medical Group is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • Deltex Medical Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Deltex Medical Group's expected growth come at a high price?
Raw Data
DB:DX9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.72x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
132.1%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.25x
Germany Market PEG Ratio Median Figure of 278 Publicly-Listed Companies 1.27x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Deltex Medical Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Deltex Medical Group's assets?
Raw Data
DB:DX9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in GBP £0.01
AIM:DEMG Share Price * AIM (2018-10-16) in GBP £0.01
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 3.99x
Germany Market PB Ratio Median Figure of 564 Publicly-Listed Companies 1.76x
DB:DX9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:DEMG Share Price ÷ Book Value per Share (both in GBP)

= 0.01 ÷ 0.01

1.65x

* Primary Listing of Deltex Medical Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Deltex Medical Group is good value based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Deltex Medical Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Deltex Medical Group has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

DX9 Future Performance

 How is Deltex Medical Group expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
132.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Deltex Medical Group expected to grow at an attractive rate?
  • Deltex Medical Group's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Deltex Medical Group's earnings growth is expected to exceed the Germany market average.
  • Deltex Medical Group's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:DX9 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:DX9 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 132.1%
DB:DX9 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 3.5%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.9%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 5.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:DX9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:DX9 Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 6 1 0 1
2018-12-31 5 -1 -1 1
DB:DX9 Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-06-30 5 -1 -2
2018-03-31 6 -1 -2
2017-12-31 6 -1 -2
2017-09-30 6 -1 -2
2017-06-30 7 -1 -2
2017-03-31 6 -1 -2
2016-12-31 6 -2 -2
2016-09-30 6 -2 -3
2016-06-30 6 -2 -3
2016-03-31 6 -2 -3
2015-12-31 6 -2 -3
2015-09-30 6 -2 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Deltex Medical Group's earnings are expected to grow significantly at over 20% yearly.
  • Deltex Medical Group's revenue is expected to grow by 3.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:DX9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Deltex Medical Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DX9 Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31 0.00 0.00 0.00 1.00
2018-12-31 -0.00 -0.00 -0.00 1.00
DB:DX9 Past Financials Data
Date (Data in GBP Millions) EPS *
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.01
2016-06-30 -0.01
2016-03-31 -0.01
2015-12-31 -0.02
2015-09-30 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Deltex Medical Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Deltex Medical Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Deltex Medical Group has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

DX9 Past Performance

  How has Deltex Medical Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Deltex Medical Group's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Deltex Medical Group does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Deltex Medical Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Deltex Medical Group's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Deltex Medical Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Deltex Medical Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DX9 Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 5.32 -2.10 5.12 0.59
2018-03-31 5.59 -2.05 5.44 0.57
2017-12-31 5.87 -2.00 5.76 0.56
2017-09-30 6.19 -1.88 5.94 0.47
2017-06-30 6.52 -1.76 6.13 0.38
2017-03-31 6.42 -2.07 6.18 0.42
2016-12-31 6.33 -2.38 6.23 0.46
2016-09-30 6.35 -2.70 6.35 0.51
2016-06-30 6.36 -3.02 6.47 0.55
2016-03-31 6.38 -3.24 6.60 0.58
2015-12-31 6.41 -3.46 6.73 0.61
2015-09-30 6.35 -3.50 6.78 0.70
2015-06-30 6.29 -3.55 6.83 0.79
2015-03-31 6.40 -3.25 6.83 0.74
2014-12-31 6.51 -2.95 6.84 0.69
2014-09-30 6.85 -2.61 6.83 0.67
2014-06-30 7.19 -2.26 6.81 0.65
2014-03-31 7.17 -2.19 6.75 0.62
2013-12-31 7.15 -2.11 6.68 0.58
2013-09-30 6.82 -2.18 6.49 0.53
2013-06-30 6.49 -2.26 6.29 0.48
2013-03-31 6.63 -2.18 6.31 0.52
2012-12-31 6.78 -2.09 6.34 0.55
2012-09-30 6.64 -2.01 6.23 0.53
2012-06-30 6.51 -1.93 6.11 0.50
2012-03-31 6.41 -1.67 5.83 0.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Deltex Medical Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Deltex Medical Group has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Deltex Medical Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Deltex Medical Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Deltex Medical Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

DX9 Health

 How is Deltex Medical Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Deltex Medical Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Deltex Medical Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Deltex Medical Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Deltex Medical Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Deltex Medical Group Company Filings, last reported 6 months ago.

DB:DX9 Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 2.45 1.87 1.07
2018-03-31 2.45 1.87 1.07
2017-12-31 1.30 1.82 0.22
2017-09-30 1.30 1.82 0.22
2017-06-30 1.78 1.69 0.19
2017-03-31 1.78 1.69 0.19
2016-12-31 2.42 1.83 0.58
2016-09-30 2.42 1.83 0.58
2016-06-30 2.51 1.59 0.52
2016-03-31 2.51 1.59 0.52
2015-12-31 1.92 1.90 0.58
2015-09-30 1.92 1.90 0.58
2015-06-30 3.13 1.75 1.31
2015-03-31 3.13 1.75 1.31
2014-12-31 4.87 2.16 2.93
2014-09-30 4.87 2.16 2.93
2014-06-30 6.11 1.77 4.22
2014-03-31 6.11 1.77 4.22
2013-12-31 3.37 2.31 1.46
2013-09-30 3.37 2.31 1.46
2013-06-30 3.22 2.09 1.46
2013-03-31 3.22 2.09 1.46
2012-12-31 2.11 2.12 0.67
2012-09-30 2.11 2.12 0.67
2012-06-30 2.48 1.89 1.32
2012-03-31 2.48 1.89 1.32
  • Deltex Medical Group's level of debt (76.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (65% vs 76.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Deltex Medical Group has sufficient cash runway for 2.4 years based on current free cash flow.
  • Deltex Medical Group has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -30.9% each year.
X
Financial health checks
We assess Deltex Medical Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Deltex Medical Group has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

DX9 Dividends

 What is Deltex Medical Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Deltex Medical Group dividends.
If you bought €2,000 of Deltex Medical Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Deltex Medical Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Deltex Medical Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:DX9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:DX9 Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Deltex Medical Group has not reported any payouts.
  • Unable to verify if Deltex Medical Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Deltex Medical Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Deltex Medical Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Deltex Medical Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Deltex Medical Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Deltex Medical Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

DX9 Management

 What is the CEO of Deltex Medical Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andy Mears
AGE 49
TENURE AS CEO 0.6 years
CEO Bio

Mr. Andrew Jonathan Mears, also known as Andy, has been Chief Executive Officer and Director of Deltex Medical Group plc since June 2018. Mr. Mears was Managing Director of Deltex Medical Group plc since 2015 until June 2018. Mr. Mears served as Group Sales Director of Deltex Medical Group plc since 2010 until 2015. Mr. Mears joined Deltex Medical in 1989 as an Electronics Engineer. Mr. Mears has held a number of roles, including Product & Production Manager and Operations Director.

CEO Compensation
  • Insufficient data for Andy to compare compensation growth.
  • Insufficient data for Andy to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure of the Deltex Medical Group management team in years:

3.3
Average Tenure
  • The tenure for the Deltex Medical Group management team is about average.
Management Team

Jonathan Shaw

TITLE
Finance Director
COMPENSATION
£138K
AGE
49
TENURE
3.3 yrs

Andy Mears

TITLE
CEO & Director
AGE
49
TENURE
0.6 yrs

Graham Lowe

TITLE
Chief Operating Officer
TENURE
3 yrs

Marion Lee

TITLE
Human Resources Director
TENURE
3.8 yrs

Peter Rose

TITLE
International Sales Director
TENURE
9 yrs

Tim Taylor

TITLE
Commercial Director
TENURE
13 yrs

Mark Baylis

TITLE
Quality & Regulatory Affairs Director
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Deltex Medical Group board of directors in years:

4.6
Average Tenure
59.5
Average Age
  • The tenure for the Deltex Medical Group board of directors is about average.
Board of Directors

Nigel Keen

TITLE
Chairman
COMPENSATION
£33K
TENURE
23 yrs

Jonathan Shaw

TITLE
Finance Director
COMPENSATION
£138K
AGE
49
TENURE
3.3 yrs

Andy Mears

TITLE
CEO & Director
AGE
49
TENURE
0.6 yrs

Charles Cazalet

TITLE
Non Executive Director
COMPENSATION
£24K
AGE
70
TENURE
10.8 yrs

Duncan Nichol

TITLE
Non Executive Director
COMPENSATION
£24K
AGE
77
TENURE
14.5 yrs

Mark Wippell

TITLE
Non-Executive Director
COMPENSATION
£24K
TENURE
4.6 yrs

Chris Jones

TITLE
Non-Executive Director
COMPENSATION
£18K
TENURE
3.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Aug 18 Buy Nigel Keen Individual 24. Aug 18 24. Aug 18 2,000,000 €0.01 €17,999
23. Aug 18 Buy Nigel Keen Individual 22. Aug 18 22. Aug 18 1,000,000 €0.01 €9,000
30. Jul 18 Buy Andrew Mears Individual 27. Jul 18 27. Jul 18 2,234,222 €0.01 €19,885
27. Jul 18 Buy Nigel Keen Individual 26. Jul 18 26. Jul 18 6,000,000 €0.01 €50,501
X
Management checks
We assess Deltex Medical Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Deltex Medical Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

DX9 News

External News
Loading...
Simply Wall St News

DX9 Company Info

Map
Description

Deltex Medical Group plc manufactures and sells oesophageal doppler monitoring (ODM) systems in the United Kingdom, the United States, Spain, Canada, and internationally. It develops, designs, manufactures, and markets medical devices that generate low frequency ultrasound signal to visualize and measure blood flow in the central circulation. The company offers CardioQ-ODM that allows clinicians to guide fluid and drug administration during surgery and critical care; CardioQ-ODM+, a fluid management and cardiac output monitoring system to measure flow and pressure directly for adults and paediatrics; high definition impedance cardiography, a non-invasive cardiac output and fluid status monitoring system; oesophageal doppler probes; and FORE-SIGHT elite absolute tissue oximetry, which allows clinicians to treat cerebral desaturation events. It also provides high definition impedance cardiography for non-invasive cardiac output and fluid status monitoring; and intubrite video laryngoscopes and laryngoscopes. The company was incorporated in 2000 and is based in Chichester, the United Kingdom.

Details
Name: Deltex Medical Group plc
DX9
Exchange: DB
Founded: 2000
£4,943,919
492,663,367
Website: http://www.deltexmedical.com
Address: Deltex Medical Group plc
Terminus Road,
Chichester,
West Sussex, PO19 8TX,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM DEMG Ordinary Shares London Stock Exchange AIM Market GB GBP 20. Jul 2000
OTCPK DTXM.F Ordinary Shares Pink Sheets LLC US USD 20. Jul 2000
DB DX9 Ordinary Shares Deutsche Boerse AG DE EUR 20. Jul 2000
Number of employees
Current staff
Staff numbers
56
Deltex Medical Group employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/13 21:25
End of day share price update: 2018/10/16 00:00
Last estimates confirmation: 2018/09/24
Last earnings filing: 2018/09/24
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.